US 12,293,001 B2
Referential data grouping and tokenization for longitudinal use of de-identified data
Jay Sultan, Bogart, GA (US); Jeffrey M. Diamond, Milton, GA (US); Jill Luber, Atlanta, GA (US); Victor E. Tavernini, Davie, FL (US); Emily Mortimer, Bloomington, MN (US); Raghunandan Valluri, Cumming, GA (US); Theresa Roseanne Wu, Winter Garden, FL (US); Charles Edwards Morton, Austin, TX (US); and Brian Richard Mullin, Budd Lake, NJ (US)
Assigned to LexisNexis Risk Solutions FL In., Boca Raton, FL (US)
Filed by LexisNexis Risk Solutions FL Inc., Boca Raton, FL (US)
Filed on Apr. 20, 2022, as Appl. No. 17/724,908.
Claims priority of provisional application 63/179,014, filed on Apr. 23, 2021.
Prior Publication US 2022/0343021 A1, Oct. 27, 2022
Int. Cl. G06F 21/62 (2013.01); G16H 10/60 (2018.01); G16H 70/40 (2018.01)
CPC G06F 21/6254 (2013.01) [G16H 10/60 (2018.01); G16H 70/40 (2018.01)] 26 Claims
OG exemplary drawing
 
1. A computer-implemented method for detecting and preventing potential adverse reactions of prescription drug combinations, the method comprising:
receiving, at a main tokenizer, and from a trusted 3rd party in communication with one or more pharmacies, one or more corresponding data sets comprising:
a subset of a plurality of personally identifiable information (PII) fields corresponding to a patient seeking a prescription drug; and
a drug identifier corresponding to the prescription drug;
determining, with one or more computer processors, relationships among the subset of the plurality of PII fields and the drug identifier by:
creating a core join data structure with at least a portion of all available patient information;
splitting the core join data structure into persisted parts, wherein the persisted parts are configured for updating a shared structure between versions in memory to reduce disk utilization; and
updating the shared structure between the versions in the memory;
resolving, by the main tokenizer in communication with a universal reference database (URD) and based on the updated shared structure, an identity of the patient based on the subset of the plurality of PII fields and a persistent universal identifier corresponding to the patient;
linking a unique patient-centric token (PCT) to the patient based on the resolving;
determining, based on the one or more data sets, one or more prescription drug combinations associated with the resolved identity of the patient;
for each of the one or more prescription drug combinations:
comparing the drug identifier against safety data;
determining, based on the comparing, a potential adverse reaction associated with the one or more prescription drug combinations; and
outputting the PCT and an indication of the potential adverse reaction.